To register for or join any of the upcoming webinars, please click on the individual link below for the dates you would like to attend and register.
April/May/June 2021 Webinar Dates
- April 22, 2021 11:00 AM EDT
- April 29, 2021 at 11:00 am ET
- May 6, 2021 at 11:00 am ET
- May 13, 2021 at 11:00 am ET
- May 20, 2021 at 11:00 am ET
- May 27, 2021 at 11:00 am ET
- June 3, 2021 at 11:00 am ET
- June 10, 2021 at 11:00 am ET
This Webinar is part of the CEO Roadshow Webinar Series where we feature small and mid-cap stocks that are on the verge of a breakout or have other near-term developments making them an attractive long-term investment opportunity.
In this webinar, we will be joined by Rodney Varner, President, and CEO of Genprex.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, that trades on the NASDAQ under ticker GNPX.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso.
For more information, please visit the Company’s web site at www.genprex.com
CEORoadshow.com is committed to providing our readers with useful information on publicly traded companies. CEORoadshow.com sometimes contracts with third parties or publicly traded companies and receives compensation from them in the form of cash and sometimes restricted securities as payment for publishing information and opinions about the company and the trading market for their securities. CEORoadshow.com content should not be considered to be independent publications concerning the company.
Neither CEOROADSHOW.COM or any of its principals currently own or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, CEOROADSHOW.COM/disclaimer.